The conversation explores the nuances of the manuscript,providing a practical perspective on translating these consensus recommendations into clinical operations.
Assessing the Burden of Immunosuppression: Evaluating the cumulative risk factors that predispose CAR T recipients to infection, including heavy pretreatment and the effects of lymphodepletion.
Prophylaxis Optimization: Critical considerations regarding the timing, selection, and duration of antimicrobial regimens in the post-CAR T setting.
Managing Hypogammaglobulinemia: A pragmatic look at IVIG replacement strategies, balancing emerging clinical evidence with institutional protocols and global product shortages.
Addressing Evidence Gaps: Insider insights into the expert panel’s deliberations on "grey areas," such as the management of CMV reactivation and optimal post-therapy vaccination schedules.
The Pediatric-Adult Continuum: Ensuring that prevention and management strategies are robust and applicable across the full age spectrum of CAR-T recipients.
This episode provides essential context for cliniciansseeking to move beyond the published guidelines and operationalize these bestpractices with greater precision and confidence.
Thank you to Johnson & Johnson and Legend Biotech forsupporting this episode.
Podden och tillhörande omslagsbild på den här sidan tillhör
ASTCT. Innehållet i podden är skapat av ASTCT och inte av,
eller tillsammans med, Poddtoppen.